Skip to content
MarketScale
Demo
‹ Back to Industries

Sciences

When to Plant for Optimal Growth: Best Seasons and Times of the Year

For Optimal Growth: In this informative video, we explore the optimal timing for planting trees. ISA Certified Arborist Wes Rivers advises that the best time to plant a new tree for optimal growth is during the fall, specifically in October or November. The reasoning behind this choice is that during this period, the air…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Sunny Crutchfield · Dfw Tree CareDfw Tree Care ExpertsImproper PlantingPlanting Trees
Share

Key takeaways

01

For Optimal Growth: In this informative video, we explore the optimal timing for planting trees.

02

ISA Certified Arborist Wes Rivers advises that the best time to plant a new tree for optimal growth is during the fall, specifically in October or November.

03

The reasoning behind this choice is that during this period, the air…

For Optimal Growth: In this informative video, we explore the optimal timing for planting trees. ISA Certified Arborist Wes Rivers advises that the best time to plant a new tree for optimal growth is during the fall, specifically in October or November. The reasoning behind this choice is that during this period, the air temperatures have cooled down, reducing stress on the young tree. Simultaneously, the soil retains the warmth from the preceding hot summer, creating favorable conditions for robust root growth. Additionally, this timing allows the tree to establish itself over the course of eight to nine months before facing the challenges of the next scorching summer. Discover the wisdom behind choosing the perfect season for tree planting and ensure the health and vitality of your new green additions to the environment.

Discover more reasons why working with an arborist can safeguard the future of your trees!

Are you looking for a sustainable Dallas-Fort Worth tree care company that prioritizes the health and longevity of your North Texas trees and landscapes?

Look no further than TreeNewal, your trusted partner in tree care.

Our team of ISA Certified Arborists is dedicated to providing comprehensive tree services that ensure the vitality of your trees. From maintaining and reviving newly planted and established trees to diagnosing and treating tree diseases, fungi, and pests, we have you covered.

We specialize in proper tree diagnosis and offer tailored maintenance and treatment plans to keep your trees thriving. Our experts apply top-quality fertilizer and soil conditioning products to enhance tree health from the roots up.

At TreeNewal, we understand that many trees suffer from improper planting practices. That’s why we offer specialized techniques such as air spading, root collar excavation, and vertical mulching to improve the longevity of your trees. Our goal is to create sustainable landscapes that stand the test of time.

We also provide tree surveys and mitigation services to assist homeowners, developers, and commercial clients in meeting local city tree preservation requirements. With our expertise, you can ensure compliance while preserving the natural beauty of your surroundings.

Call TreeNewal today to schedule a consultation with our knowledgeable team. Let us be your partners in preserving the beauty and longevity of your beloved trees.

Contact TreeNewal now and experience exceptional tree care services!

About the author

Sunny Crutchfield
Sunny CrutchfieldDigital Media Strategist

Throughout her career, Sunny Crutchfield has honed her skills in crafting data-driven campaigns, maximizing social media presence, and optimizing online content for optimal engagement and conversions. Her deep understanding of various digital channels, including social media, search engine marketing, email marketing, and content marketing, allows her to develop comprehensive and integrated campaigns that deliver tangible results.

New to MarketScale?

MarketScale is the platform Sciences companies use to turn their own experts into content like this. Want the short overview?

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

Sunny Crutchfield
Sunny Crutchfield

Digital Media Strategist

Throughout her career, Sunny Crutchfield has honed her skills in crafting data-driven campaigns, maximizing social media presence, and optimizing online content for optimal engagement and conversions. Her deep understanding of various digital channels, including social media, search engine marketing, email marketing, and content marketing, allows her to develop comprehensive and integrated campaigns that deliver tangible results.

LinkedIn

For Sciences teams

See how Sciences teams use MarketScale →

Executive Thought Leadership

Explore Channels

Industry news, analysis, and expert perspectives

Professional AV›Engineering & Construction›Education Technology›Healthcare›Energy›Software & Technology›Retail›Business Services›Industrial IoT›Sports & Entertainment›Transportation›Sciences›Building Management›Food & Beverage›Architecture & Design›Hospitality›
Keep exploring

More from Sciences

Sciences hubMore expert Sciences coverage.Explore →Executive Thought LeadershipPut researchers on the record.Explore →FinThriveComplex topics, made clear.Explore →State of GEO & AI VisibilityHow B2B brands get cited by AI search.Explore →